Thu Mar 16, 2023 – 12:26 pm EDT
WASHINGTON, D.C. (LifeSiteNews) — The U.S. Food & Drug Administration (FDA) is approving booster doses of Pfizer’s COVID-19 shot for children as young as six months based on a trial of just 24 patients.
The FDA announced March 14 that it is amending its emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine, Bivalent, to allow a single booster dose for children between six months and four years, at least two months after being initially vaccinated.
“Currently available data show that vaccination remains the best defense against severe disease, hospitalization and death caused by COVID-19 across all age groups, and we encourage all eligible individuals to make sure that their vaccinations are up to date with a bivalent COVID-19 vaccine,” claimed Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research.
Buried in the press release, however, was the revelation that “among individuals 6 months of age and older, safety was assessed in participants in two clinical studies,” and that for the 6-23 months age group there were only 24 participants. The 2-4 year age group had 36.
For the first group, “most common side
The remainder of this article is available in its entirety at LifeSite News
The views expressed in this news alert by the author do not directly represent that of The Official Street Preachers or its editors